PRKCA and colorectal carcinoma: In the present study, we provide evidence that PKCα, a physiological enhancer of β-catenin degradation [19] and a repressor of β-catenin co-transcriptional activity ([18] and see Figure S1), also could be an attractive candidate drug target for CRC treatment.